Opinion|Videos|July 2, 2024
AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety
The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.
Advertisement
Episodes in this series
- What are the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations on the treatment of patients with HE?
Vilstrup et al 2014 ,EASL 2022 - managing covert HE
- managing overt HE
- In primary care we are somewhat familiar with rifaximin. For patients with HE, can the primary care clinician prescribe it or does the hepatologist/gastroenterologist have to prescribe it?
- What are some reasons why rifaximin is under prescribed by PCP’s?
- What are strategies to help increase uptake?
- What do we know about treatment adherence of rifaximin?
- What data do we have on the safety and efficacy of rifaximin in HE?
Yu et al 2021 ,Zacharias et al 2023 - Alone and as combination therapy
- How do you handle payer approval, what is required?
Advertisement
Related to this article
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
Advances in Treating High-Impact Psoriasis from EADV 2026
3
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data
5